• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Self-Administered Remifentanil PCA or Pethidine Injection for Labor Pain?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Patients may receive narcotics such as pethidine during labor
    • Of those, many women will also receive other analgesics and epidural blocks
  • Patient-controlled anesthesia, such as remifentanil PCA, is an alternative but not commonly used
  • Wilson et al. (The Lancet, 2018) compared remifentanil PCA with pethidine for labor pain and subsequent conversion to epidural analgesia

METHODS:

  • Open-label, multicenter, randomized controlled trial (RCT)
    • Women in labor age ≥16 years requesting opioid
    • >37 weeks | Singleton | Cephalic presentation
  • Patients were randomized to either
    • Intravenous remifentanil PCA group (40 μg bolus on demand with a 2 min lockout)
    • Pethidine IM group (100 mg every 4 h, up to 400 mg in 24 h)
  • Primary outcome: Proportion of women who received epidural analgesia after enrollment for pain relief in labor

RESULTS:

  • 401 women were randomized
    • 201 remifentanil PCA | 199 pethidine IM
  • Proportions of epidural conversion were
    • Remifentanil PCA group: 19%
    • Pethidine group: 41%
    • Risk ratio 0.48; 95% CI, 0.34–0.66 (p<0.0001)
  • Proportions of instrumental vaginal delivery
    • Remifentanil PCA group: 15%
    • Pethidine group: 26%
    • RR 0.59; 95% CI, 0.4-0.88 (p=0.008)
  • There were no serious adverse events in either group

CONCLUSION:

  • Remifentanil PCA decreased need for epidural and instrumental vaginal delivery
  • Data consistent with previous low-quality evidence
  • The authors consider patient-administered PCA to be a superior approach for labor pain

Learn More – Primary Sources:

Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Cochrane Review: What are the Risks and Benefits of Epidural Analgesia During Labor?
Does Epidural Anesthesia Impact the Second Stage of Labor?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site